Brightspring Health Services . Tangible Equity Unit Stock Earnings Reports

BrightSpring reported strong Q1 2026 results with revenue of $3.6 billion (up 26% YoY) and adjusted EBITDA of $190 million (up 45% YoY), driven by both Pharmacy Solutions ($3.2B revenue) and Provider Services ($442M). Key operational highlights include robust script growth in Specialty (~30% YoY) and Infusion (double-digit growth), high patient satisfaction and quality metrics across segments, and improvements in gross profit per script driven by mix (specialty/infusion growth), brand-to-generic shifts, purchasing benefits, and fee-for-service activity. The company completed the divestiture of Community Living for ~$811M net proceeds (before tax) and used proceeds to strengthen the balance sheet: net debt ~$1.7B and leverage of 2.27x (pro forma ~2.40x factoring expected Q2 taxes). Guidance (continuing operations, excludes divested Community Living and unclosed acquisitions) for full-year 2026: revenue $14.725B–$15.225B, adjusted EBITDA $795M–$825M (including ~$30M contribution from acquired Amedisys/LHC assets). Management emphasized continued focus on scaling LDDs and infusion opportunities, geographic tuck-in M&A within a disciplined leverage target (mid-2x to <3x), ongoing investments in automation/AI and operational efficiencies, and pursuing value-based care initiatives (including potential ACO participation). IRA-related impacts and brand-to-generic transitions were reiterated: Home & Community Pharmacy IRA headwind ~ $175M for 2026; Specialty/Infusion IRA impact ~ $181M; branded-to-generic conversions ~ $250M, with ~$15M of EBITDA mitigation expected.